Navigation Links
Nautilus Neurosciences and Tribute Pharmaceuticals Announce Exclusive Canadian License for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine
Date:11/16/2010

>CAMBIA is not indicated for prophylactic therapy or for cluster headache.

Important Safety Information (United States)

WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS NSAIDs, including CAMBIA, may increase the risk of serious cardiovascular (CV) thrombotic events, myocardial infarction, and stroke, which can be fatal. Risk may increase with duration of use or in patients with CV disease or risk factors for CV disease. CAMBIA is contraindicated for peri-operative pain in coronary artery bypass graft surgery. NSAIDs increase the risk of gastrointestinal (GI) adverse events, including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk.

Use the lowest effective dose for the shortest possible duration. Long-term administration of NSAIDs can result in serious and potentially fatal events, including CV thrombotic events or GI reactions.

CAMBIA is contraindicated in patients with hypersensitivity to diclofenac or other NSAIDs, and in patients with preexisting asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic-like reactions have been reported in such patients. Anaphylactic reactions may also occur in patients with the aspirin triad or in patients without prior exposure to CAMBIA. CAMBIA is contraindicated in patients with the aspirin triad. Discontinue immediately if an anaphylactic reaction occurs.

Renal papillary necrosis and other renal injury may occur with long-term use of NSAIDs. Use CAMBIA with caution in patients at risk, including the elderly, those taking diuretics or ACE inhibitors, those with renal impairment, heart failure, or liver impairment. CAMBIA is not recommended in patients with advanced renal disease.

Use caution when prescribing CAMBIA with drugs known to be
'/>"/>

SOURCE Nautilus Neurosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Nautilus Neurosciences and Mission Pharmacal Announce Exclusive Co-Promotion Agreement for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine to the Womens Health Market
2. US WorldMeds Acquires Solstice Neurosciences
3. Blanchette Rockefeller Neurosciences Institute and Inverness Medical Innovations to Develop Commercial Test to Detect Early Alzheimers Disease
4. Intellect Neurosciences, Inc. Announces Independent Studies on Copper Binding Properties of its Lead Candidate OXIGON(TM)
5. Neurosciences Institute Discovers Drug Extends Stroke Treatment Time to 24 Hours, Repairs Brain Tissue
6. Intellect Neurosciences, Inc. and Medical Research Council Technology (U.K.) Reach Important Milestone in Generating an Alzheimers Therapeutic Antibody
7. Knopp Neurosciences Receives Orphan Designation for KNS-760704 for Treatment of ALS
8. Knopp Neurosciences Initiates Phase 1 Clinical Trial of KNS-760704 in ALS Development Program
9. Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease
10. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
11. Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... September 22, 2014 Final ... 25   The second edition of the ... excited to announce the final nominations for the 2014 ... on the evening of September 25 at The Taj Mahal Palace, ... applicants based on a variety of qualitative and quantitative ...
(Date:9/22/2014)... Sept. 22, 2014  Elusys Therapeutics, Inc. (Elusys), ... infectious disease, today announced it has completed three ... obiltoxaximab (ETI-204). Obiltoxaximab is an anti-toxin in development ... from these studies support the safety and tolerability ... the intended therapeutic dose. The conclusion of these ...
(Date:9/22/2014)... , Sept. 22, 2014  Aethlon Medical, ... therapeutic devices to address infectious disease, cancer and ... Advanced Research Projects Agency (DARPA) has informed the ... to proceed with year four of a five-year ... on September 30, 2011 under DARPA,s Dialysis-Like Therapeutics ...
Breaking Medicine Technology:Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 2Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 2Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 4Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 5Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 6Aethlon Medical Receives Notice of DARPA Contract Renewal 2Aethlon Medical Receives Notice of DARPA Contract Renewal 3Aethlon Medical Receives Notice of DARPA Contract Renewal 4
(Date:9/22/2014)... Hamilton, ON (September 22, 2014) South Asians living ... and double the rate of diabetes compared with while ... was published today in the Canadian Medical Association ... http://www.cmajopen.ca/content/2/3/E183.full , One of the fastest-growing ethnic ... million South Asian people living in Canada, comprising about ...
(Date:9/22/2014)... NJ. September 22, 2014. Kessler researchers have published ... 10-week psychoeducational wellness program in people with multiple ... overall mental health, perceived stress, and pain. ... for individuals living with MS: Description and outcomes" ... in the International Journal of MS Care ...
(Date:9/22/2014)... News) -- Two new prescription devices approved by the ... relief for people with migraine headaches who don,t tolerate ... One device -- the Cefaly -- is designed to ... -- is meant to be used when migraines first ... have been looking for alternative migraine treatments. Because these ...
(Date:9/22/2014)... Severe weather can occur with little warning, so ... part of National Preparedness Month, Amica Insurance is offering ... the unexpected:, , Build an emergency supply kit. ... one gallon of water per person per day for at least ... that includes pets so your family knows what to do and ...
(Date:9/22/2014)... New York / Westchester County, NY (PRWEB) September 22, ... Plastic Surgery (NYGPS) has joined the Department of Surgery ... The newly named Mount Sinai Doctors New York Group ... and the lower Hudson Valley access to a team ... plastic surgery techniques. Additionally, C. Andrew Salzberg, MD, ...
Breaking Medicine News(10 mins):Health News:Higher risk of heart disease for South Asians in Canada 2Health News:Noninvasive Devices May Help Migraines, FDA Says 2Health News:Amica Shares Tips for National Preparedness Month 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 3
... WashingtonThe American College of Physicians (ACP) today applauded Rep. ... for their bipartisan introduction of the Medicare Physician Payment ... is designed to eliminate the flawed Sustainable Growth Rate ... scheduled cuts. The SGR cuts threaten to drive physicians ...
... Black Americans who suffer cardiac arrest in public places are ... automated external defibrillators, a new study has found. Cardiac ... to stop beating. CPR and automated external defibrillators (AEDs) -- ... a normal rhythm -- can help a cardiac arrest victim ...
... May 11 (HealthDay News) -- Heart attack survivors are more ... it,s safe, a new study shows. University of Chicago ... study. Among patients who were sexually active before their heart ... discharged from the hospital were 1.5 times more likely to ...
... Brophy Marcus HealthDay Reporter , FRIDAY, May ... their periods, but new research suggests weight-loss surgery can ... hair growth and skin problems that often accompany significant ... the United States," said study author Chandhana Paka, a ...
... mobility now have access to specialized exercise equipment in ... the University of Alberta and the Spinal Cord Injury ... electrical stimulation (FES) rehabilitation therapy machines are now available ... Faculty of Physical Education and Recreation at the U ...
... disease allow physicians to tailor treatment to a patient,s ... many types of cancer the molecular subtypes are more ... that can affect a patient,s response to therapy. ... the first time that lung cancer molecular subtypes correlate ...
Cached Medicine News:Health News:ACP applauds introduction of bipartisan bill to eliminate Medicare SGR formula 2Health News:Blacks Less Likely to Get Help on Scene After Cardiac Arrest: Study 2Health News:Blacks Less Likely to Get Help on Scene After Cardiac Arrest: Study 3Health News:Sex After Heart Attack? Doc's OK May Be Key 2Health News:Weight-Loss Surgery May Also Help Menstruation, Skin, Hair 2Health News:Weight-Loss Surgery May Also Help Menstruation, Skin, Hair 3Health News:Partnership provides inclusive workout 2Health News:Partnership provides inclusive workout 3Health News:Molecular subtypes and genetic alterations may determine response to lung cancer therapy 2
... innovative stent allows the physician to intubate the ... with just topical anesthetic drops., ,The SRS is ... in three lengths 25mm, 30mm and 35mm (disposable ... stent is an anchor-shaped head to provide fixation. ...
... or somatomedin-C, is a peptide highly dependent ... promoting activity. IGF-I is transported in serum ... of growth disorders, measurements of IGF-I are ... hormone secretion. A normal plasma or serum ...
... is a high-throughput immunoassay system built around ... 2000 with the important addition of Logic ... to be designed for optimal performance with ... for critical assays such as the cardiac ...
... For The Detection ... Uses Of C-Peptide Measurement:, ... fasting hypoglycemia , Assisting ... diabetes mellitus , Differentiating ...
Medicine Products: